JP2021524850A - ＲＯＲγ調節剤としての三環スルホン化合物 - Google Patents

ＲＯＲγ調節剤としての三環スルホン化合物 Download PDF

Info

Publication number
JP2021524850A
JP2021524850A JP2020564431A JP2020564431A JP2021524850A JP 2021524850 A JP2021524850 A JP 2021524850A JP 2020564431 A JP2020564431 A JP 2020564431A JP 2020564431 A JP2020564431 A JP 2020564431A JP 2021524850 A JP2021524850 A JP 2021524850A
Authority
JP
Japan
Prior art keywords
disease
compound
disorder
rorγ
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524850A5 (https=
Inventor
ティ・ジー・ムラリ・ダール
ジーリィ・シャオ
マイケル・ジー・ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021524850A publication Critical patent/JP2021524850A/ja
Publication of JP2021524850A5 publication Critical patent/JP2021524850A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2020564431A 2018-05-17 2019-05-16 ＲＯＲγ調節剤としての三環スルホン化合物 Pending JP2021524850A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672802P 2018-05-17 2018-05-17
US62/672,802 2018-05-17
PCT/US2019/032555 WO2019222438A1 (en) 2018-05-17 2019-05-16 Tricyclic sulfone compound as a ror gamma modulator

Publications (2)

Publication Number Publication Date
JP2021524850A true JP2021524850A (ja) 2021-09-16
JP2021524850A5 JP2021524850A5 (https=) 2022-05-19

Family

ID=66691023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564431A Pending JP2021524850A (ja) 2018-05-17 2019-05-16 ＲＯＲγ調節剤としての三環スルホン化合物

Country Status (6)

Country Link
US (1) US10633339B2 (https=)
EP (1) EP3793978A1 (https=)
JP (1) JP2021524850A (https=)
KR (1) KR102829200B1 (https=)
CN (1) CN112119060A (https=)
WO (1) WO2019222438A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4093732A1 (en) 2020-01-24 2022-11-30 Bristol-Myers Squibb Company Tricyclic sulfones as ror gamma modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179460A1 (en) * 2015-05-07 2016-11-10 Bristol-Myers Squibb Company Tricyclic sulfones as rorϒ modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702044A (zh) 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
AR083475A1 (es) * 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
KR102506326B1 (ko) 2016-10-13 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 Ror 감마 조정제로서의 헤테로시클릭 술폰

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179460A1 (en) * 2015-05-07 2016-11-10 Bristol-Myers Squibb Company Tricyclic sulfones as rorϒ modulators

Also Published As

Publication number Publication date
KR102829200B1 (ko) 2025-07-02
WO2019222438A1 (en) 2019-11-21
KR20210009357A (ko) 2021-01-26
US10633339B2 (en) 2020-04-28
US20190352261A1 (en) 2019-11-21
CN112119060A (zh) 2020-12-22
EP3793978A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
CN105121429A (zh) 补体途径调节剂和其用途
TWI658041B (zh) Ｒｏｒ－ｇａｍｍａ之二氫吡咯并吡啶抑制劑
WO2022261210A1 (en) Kras modulators and uses thereof
FR2561244A1 (fr) Composes heterocycliques du type tetrahydrocarbazolone, procede pour leur preparation et composition pharmaceutique les comprenant
US20250382309A1 (en) Methods and materials for increasing transcription factor eb polypeptide levels
CN104936972A (zh) 具有抗炎活性的甘草次酸衍生物
JP7340023B2 (ja) テトラゾロン置換ステロイド及びその使用
JP2017529402A (ja) 自己免疫疾患の処置
JP2001519805A (ja) 化合物
JP2021524850A (ja) ＲＯＲγ調節剤としての三環スルホン化合物
JP3164372B2 (ja) 融合インドール及びキノキサリン誘導体、その製造および使用
EP0455596B1 (de) Substituierte Indole
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
DE60027461T2 (de) Megluminsalz einer spezifischen Chinolinsäure-Verbindung mit NMDA Rezeptor-Aktivität
JP7726893B2 (ja) ＲＯＲγ調節剤としての三環スルホン化合物
JP3270524B2 (ja) 新規イサチンオキシム誘導体、その製造方法および使用方法
EP0548017A1 (de) Neue Thiazole
EP0548018A1 (de) Neue Imidazole
US7345079B2 (en) Treatment of disorder related to low cyclic GMP levels
JP2024539996A (ja) ターフェニル化合物の安息香酸塩の製造方法
HK40093954B (en) Substituted 4‑([1,2,4]triazolo[1,5‑a]pyridin‑6‑yl)thiophene‑2‑carboxamide derivatives and use thereof
HK40093954A (en) Substituted 4‑([1,2,4]triazolo[1,5‑a]pyridin‑6‑yl)thiophene‑2‑carboxamide derivatives and use thereof
JP2020537664A (ja) （２２Ｅ）−（２４Ｒ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３の結晶化手順
JPH0373547B2 (https=)
JPH0429678B2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240130